Consensus statement for treatment protocols in pressurized intraperitoneal aerosol chemotherapy (PIPAC).
PIPAC
cisplatin
doxorubicin
oxaliplatin
peritoneal metastasis
standardisation
treatment protocol
Journal
Pleura and peritoneum
ISSN: 2364-768X
Titre abrégé: Pleura Peritoneum
Pays: Germany
ID NLM: 101710063
Informations de publication
Date de publication:
01 Mar 2022
01 Mar 2022
Historique:
received:
10
01
2022
accepted:
02
02
2022
entrez:
23
5
2022
pubmed:
24
5
2022
medline:
24
5
2022
Statut:
epublish
Résumé
Safe implementation and thorough evaluation of new treatments require prospective data monitoring and standardization of treatments. Pressurized intraperitoneal aerosol chemotherapy (PIPAC) is a promising alternative for the treatment of patients with peritoneal disease with an increasing number of suggested drug regimens. The aim was to reach expert consensus on current PIPAC treatment protocols and to define the most important research topics. The expert panel included the most active PIPAC centers, organizers of PIPAC courses and principal investigators of prospective studies on PIPAC. A comprehensive literature review served as base for a two-day hybrid consensus meeting which was accompanied by a modified three-round Delphi process. Consensus bar was set at 70% for combined (strong and weak) positive or negative votes according to GRADE. Research questions were prioritized from 0 to 10 (highest importance). Twenty-two out of 26 invited experts completed the entire consensus process. Consensus was reached for 10/10 final questions. The combination of doxorubicin (2.1 mg/m The current consensus should help to limit heterogeneity of treatment protocols but underlines the utmost importance of further research.
Identifiants
pubmed: 35602919
doi: 10.1515/pp-2022-0102
pii: pp-2022-0102
pmc: PMC9069497
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1-7Informations de copyright
© 2022 Olivia Sgarbura et al., published by De Gruyter, Berlin/Boston.
Déclaration de conflit d'intérêts
Competing interests: The following disclosure were made: MH: 1. Research funding (institution): Nestlé health science. 2. Speaker honorary (institution): MSD, Nestlé, Fresenius, Capnomed, Encare. 3. Boards: ERAS society: chair education, ISSPP: chair education. MR: 1.Research funding: Capnomed GmbH, Fisher Paykel, Alesi Surgical. 2. Speaker honorary: Boerhinger Ingelheim. 3. Stock shareholder: Capnomed GmbH. MP: Research funding: Capnomed GmbH, IDmed, INSERM laboratory unit. XD: Speaker honorary: Capnomed GmbH, Consultant for Latin America. WPY: Speaker honorary: Astra Zeneca, BMS, Eli Lilly, Novartis. The rest of the authors have no competing interests.
Références
Lancet Oncol. 2020 Sep;21(9):1147-1154
pubmed: 32717180
Nat Rev Clin Oncol. 2010 Feb;7(2):108-15
pubmed: 20010898
Pleura Peritoneum. 2018 Jun 08;3(2):20180112
pubmed: 30911657
Eur J Surg Oncol. 2019 Dec;45(12):2386-2391
pubmed: 31092362
Pleura Peritoneum. 2018 Jun 12;3(2):20180107
pubmed: 30911655
Ann Surg Oncol. 2021 Sep;28(9):5311-5326
pubmed: 33544279
Eur J Surg Oncol. 2020 Dec;46(12):2270-2275
pubmed: 32561205
Eur J Surg Oncol. 2022 Apr;48(4):789-794
pubmed: 34785087
BJS Open. 2020 Apr;4(2):206-215
pubmed: 31957257
Eur J Surg Oncol. 2017 Jun;43(6):1102-1109
pubmed: 28431896
Allergy. 2021 Jun;76(6):1882-1885
pubmed: 33616981
Cancer Chemother Pharmacol. 2019 Mar;83(3):425-430
pubmed: 30511218
Gynecol Oncol. 2018 Jul;150(1):23-30
pubmed: 29743140
Eur J Cancer. 2020 Nov;140:37-44
pubmed: 33039812
Surg Oncol. 2018 Jun;27(2):275-279
pubmed: 29937182
Eur J Surg Oncol. 2020 Dec;46(12):2311-2323
pubmed: 32826114
Ann Surg Oncol. 2021 Jul;28(7):3861-3862
pubmed: 33216262
BJS Open. 2020 Feb;4(1):157-163
pubmed: 32011810
Eur J Surg Oncol. 2021 Jan;47(1):149-156
pubmed: 32900609
Clin Cancer Res. 2021 Apr 1;27(7):1875-1881
pubmed: 33148667
Ann Surg Oncol. 2014 Feb;21(2):553-9
pubmed: 24006094
Langenbecks Arch Surg. 2021 May;406(3):505-520
pubmed: 33640992
Cancers (Basel). 2021 Mar 03;13(5):
pubmed: 33802269
Cancer Treat Rev. 2019 Mar;74:15-20
pubmed: 30665053
Lancet Oncol. 2019 Jul;20(7):e368-e377
pubmed: 31267971
J Clin Oncol. 2015 Jan 20;33(3):278-84
pubmed: 25512456
Lancet Gastroenterol Hepatol. 2019 Oct;4(10):761-770
pubmed: 31371228
Adv Healthc Mater. 2020 Aug;9(16):e2000655
pubmed: 32548967
J Clin Med. 2018 Dec 19;7(12):
pubmed: 30572653
Ann Surg Oncol. 2021 Jul;28(7):3852-3860
pubmed: 33216263
Eur J Surg Oncol. 2020 Dec;46(12):2292-2310
pubmed: 32873454
Lancet. 2009 Sep 26;374(9695):1105-12
pubmed: 19782876
Dis Colon Rectum. 2020 Feb;63(2):242-255
pubmed: 31914116
Eur J Surg Oncol. 2019 Dec;45(12):2302-2309
pubmed: 31221459
Pleura Peritoneum. 2021 Feb 12;6(1):39-45
pubmed: 34222648